Gagnon Robert E. 4

What Happened Robert E. Gagnon, Chief Financial Officer of Opus Genetics (IRD), received a grant of 400,000 restricted stock units (RSUs) on January 22, 2026. The Form 4 reports an acquisition price of $0.00 for the award (i.e., no cash paid at grant). The RSUs are not immediate shares — they convert to common stock only as they vest.

Key Details

• Transaction date: 2026-01-22; Form 4 filed 2026-01-26 (filed 4 days after the transaction; appears outside the standard two-business-day Form 4 window).
• Grant: 400,000 RSUs; reported acquisition price $0.00 (no cash exchanged at grant).
• Vesting: RSUs vest in substantially equal quarterly installments over the next 16 quarters (footnote F1), subject to Gagnon’s continued service.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing timeliness: appears late based on the two-business-day rule for Form 4s.

Context RSU grants are a common form of executive compensation and do not involve an immediate purchase or sale of shares. Because these units vest over four years (16 quarters), they generally align executive incentives with longer-term company performance; they are not a direct market signal like an open-market purchase or sale. The reported $0 acquisition price reflects the grant structure, not the market value the shares may have when they vest.